Biotech Values

[DewDiligence]

MNTA—Can't remember what the consensus was regarding the success of the non-infringement approach, but I thought it was low. Now it seems as though it may be the strongest argument out there, and perhaps the easiest to show (as opposed to inequitable conduct, for example).

Non-infringement is the most likely avenue to victory, IMO—see #msg-59688565. This view is based on the presumption that MNTA’s 7,884,187 patent* bolsters NVS/MNTA’s defense. Regards, Dew

*http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,884,187.PN.&OS=PN/7,884,187&RS=PN/7,884,187